Miguel Perales, MD
Medical Oncology · New York, NYNPI 1922079839
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Merck at 27.6% of the total. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $2197.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$213K
- Gilead$103K
- Sanofi-aventis U.S. LLC$103K
- Omeros Corporation$71K
- Incyte Corporation$57K
- E.r. Squibb & Sons, L.L.C.$46K
- plus $177K from 19 others
Across 201 payments — averaging $6994.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$629K
- Incyte Corporation$356K
- Merck$201K
- Novartis$88K
- National Marrow Donor Program$60K
- Bristol Myers Squibb$38K
- plus $33K from 4 others
What the payments were for
- Consulting fees$434,55456%
- Speaking & faculty fees$195,68425%
- Travel & lodging$130,18317%
- Food & beverage$7,9501%
- Education$8470%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 97 | $212,581 |
| Gilead(2 entities) | 60 | $102,977 |
| Sanofi-aventis U.S. LLC | 38 | $102,950 |
| Omeros Corporation | 22 | $70,993 |
| Incyte Corporation | 25 | $56,953 |
| E.r. Squibb & Sons, L.L.C. | 17 | $46,265 |
| Sanofi US Services Inc. | 6 | $38,163 |
| Novartis | 23 | $36,732 |
| Sanofi | 5 | $17,680 |
| Sanofi Pasteur Inc. | 2 | $17,364 |
| Mallinckrodt Hospital Products Inc. | 10 | $17,073 |
| Bristol Myers Squibb | 14 | $13,210 |
| Novartis Pharma AG | 11 | $8,378 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $6,090 |
| Jazz Pharmaceuticals Inc. | 1 | $4,240 |
| CSL Behring | 2 | $3,900 |
| Cidara Therapeutics, Inc. | 1 | $3,263 |
| Astellas Pharma US Inc | 1 | $3,100 |
| Partner Therapeutics, Inc. | 1 | $2,200 |
| National Marrow Donor Program | 7 | $1,754 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Biontech SE | 1 | $1,050 |
| ADIR | 1 | $595 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $211 |
| Gamida Cell Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUROCK$133,284
- Yescarta$58,753
- KYMRIAH$38,452
- narsoplimab$31,003
- CELLEX/XTS PHOTOPHERESIS SYSTEM$16,779
- CTL019_KYMRIAH_ONCOLOGY$5,876
- CAR-T$5,600
- THYMOGLOBULIN$4,650
- DEFITELIO$4,240
- Rezzayo$3,263
- CRESEMBA$3,100
- Leukine$2,200
- PREVYMIS$1,671
- XPOVIO$1,550
- JAKAFI$1,188
- HEMANGEOL$211
How this compares
$769,293 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 64 | $2,244 |
| Tacrolimus | 13 | $501 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $220 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
- David SolitNew York$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.